PDS Biotechnology Corp Finance Lease, Liability, to be Paid, Year Four
PDS Biotechnology Corp (PDSB) had Finance Lease, Liability, to be Paid, Year Four of $26.72 thousand as of 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Notes › Commitment and Contingencies
us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour · last filed 2024-03-28
- 2023-12-31: Finance Lease, Liability, to be Paid, Year Four $26.72K.
- 2022-12-31: Finance Lease, Liability, to be Paid, Year Four $35.69K.
| Period end | Finance Lease, Liability, to be Paid, Year Four |
|---|---|
| 2023-12-31 | $26.72K 10-K · filed 2024-03-28 |
| 2022-12-31 | $35.69K 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |